Quote this publication Share Print


Opinions on drugs - Posted on Feb 06 2013

Reason for request

Re-assessment of methylphenidate-based proprietary products in attention-deficit hyperactivity disorder in response to a request from the Directorate-General for Health.


Actual benefit


The actual benefit of CONCERTA LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years and over when psychological, educational and social management alone prove insufficient.

Contact Us

Évaluation des médicaments

See also